Myriad Genetics Inc

Latest Myriad Genetics Inc News and Updates

  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018

    Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).

    By Margaret Patrick
  • uploads///AdobeStock_
    Company & Industry Overviews

    Myriad Genetics Up after UnitedHealth’s Favorable Decision

    Yesterday, Myriad Genetics submitted an 8K filing with the SEC announcing a favorable coverage decision by UnitedHealth Group.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Saw Positive Results from GeneSight Trial

    Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018

    In fiscal 2018, Myriad Genetics (MYGN) expects to witness rapid expansion in reimbursement for GeneSight based on positive results of the 1,200-patient pharmacogenomic study.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?

    In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication

    On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).

    By Margaret Patrick
  • uploads///Chart  Harvoni
    Company & Industry Overviews

    How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?

    Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.

    By Mike Benson
  • uploads///Chart  AMGN
    Miscellaneous

    The Rise of Amgen Stock in 2Q17

    Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Stock Rises on Higher Trading Volumes on June 8

    Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

    By Peter Neil
  • uploads///Pomalyst and Abraxane Revenue Part
    Earnings Report

    Pomalyst and Abraxane Revenues Are Critical for Celgene

    Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%

    Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.

    By Peter Neil
  • uploads///HALO_Portfolio
    Fund Managers

    Halozyme Therapeutics gets huge 60% increase in Iridian holdings

    Iridian Asset Management now holds 11,625,215 shares of Halozyme Therapeutics Inc. (HALO), a huge 60% increase. The fund has a 9% stake in the company.

    By Stuart McKenzie
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.